SUPN Supernus Pharmaceuticals
- 28.740
- -0.230-0.79%
- 28.740
- 0.0000.00%
Supernus Pharmaceuticals News
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (Vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals to Host Webcast to Review Interim Data From Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate of $145.832 million by 1.53 percent. This is a 6.61 percent decrease ov
Supernus Pharmaceuticals Reports Mixed Q1 Results; Reaffirms FY24 Outlook
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, Vs. Street Est of $145.8M
04:50 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M
Supernus Pharmaceuticals | 10-Q: Quarterly report
Supernus Announces First Quarter 2024 Financial Results
Press Release: Supernus Announces First Quarter 2024 Financial Results
Supernus Announces First Quarter 2024 Financial Results -- Net sales of Qelbree(R) increased 75% to $45.1 million compared to first quarter 2023. -- Total revenues were $143.6 million. To
Supernus Pharmaceuticals 1Q EPS 0c >SUPN
Supernus Pharmaceuticals 1Q EPS 0c >SUPN
Supernus Pharmaceuticals 1Q Rev $143.6M >SUPN
Supernus Pharmaceuticals 1Q Rev $143.6M >SUPN
Supernus Pharmaceuticals 1Q Net $124,000 >SUPN
Supernus Pharmaceuticals 1Q Net $124,000 >SUPN
M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8's Trademark In Latin America
M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ('Supernus'), a biopharmaceutical c
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Shares May Have Run Too Fast Too Soon
With a median price-to-sales (or "P/S") ratio of close to 3x in the Pharmaceuticals industry in the United States, you could be forgiven for feeling indifferent about Supernus Pharmaceuticals, Inc.'s
Busy Philipps Shines Spotlight on ADHD in Women and Shares Her Qelbree Story
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with QelbreeThe percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Analysis
Price Target
No Data
